CereVasc Announces Publication of First-in-Human Case Report of its eShunt System for the Treatment of Communicating Hydrocephalus
BOSTON, Dec. 7, 2021 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, announced today the publication of a case report detailing the first treatment in a study of its eShuntâ System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century old neurosurgical procedure associated with frequent failure, infection risk and high costs.